Elixir: Elixir Medical Corporation: Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024

Twelve-month primary and secondary endpoints data compare DynamX Coronary Bioadaptor System with a contemporary drug-eluting stent (DES) in a broad patient population Elixir Medical, a developer o...